Literature DB >> 12609707

Lack of initiation activity in rat liver of low doses of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline.

Shoji Fukushima1, Hideki Wanibuchi, Keiichirou Morimura, Min Wei, Dai Nakae, Yoichi Konishi, Hiroyuki Tsuda, Nobuo Takasuka, Katsumi Imaida, Tomoyuki Shirai, Masae Tatematsu, Tetsuya Tsukamoto, Masao Hirose, Fumio Furukawa.   

Abstract

It has been generally accepted that genotoxic carcinogens have no threshold in exerting their potential for cancer induction. However, the non-threshold theory can be challenged for cancer risk assessment in humans. Here we examined low dose carcinogenicity of a food-derived, genotoxic hepatocarcinogen, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), using an in vivo medium-term bioassay to detect initiating activity for rat hepatocarcinogenesis. With MeIQx initiation at various doses followed by administration of phenobarbital, a well known hepatopromoter, no induction of glutathione S-transferase placental form-positive foci, assessed as preneoplastic lesions, was noted at doses of 0.001-1 ppm. The results imply a no-observed effect level for hepatocarcinogenicity with this genotoxic agent.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609707     DOI: 10.1016/s0304-3835(02)00631-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  2 in total

Review 1.  Mode of action-based risk assessment of genotoxic carcinogens.

Authors:  Andrea Hartwig; Michael Arand; Bernd Epe; Sabine Guth; Gunnar Jahnke; Alfonso Lampen; Hans-Jörg Martus; Bernhard Monien; Ivonne M C M Rietjens; Simone Schmitz-Spanke; Gerlinde Schriever-Schwemmer; Pablo Steinberg; Gerhard Eisenbrand
Journal:  Arch Toxicol       Date:  2020-06-15       Impact factor: 5.153

Review 2.  Quantitative Approaches to Assess Key Carcinogenic Events of Genotoxic Carcinogens.

Authors:  Shoji Fukushima; Min Gi; Masaki Fujioka; Anna Kakehashi; Hideki Wanibuchi; Michiharu Matsumoto
Journal:  Toxicol Res       Date:  2018-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.